A detailed history of Bray Capital Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bray Capital Advisors holds 4,911 shares of BMY stock, worth $276,096. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,911
Previous 4,854 1.17%
Holding current value
$276,096
Previous $201,000 26.37%
% of portfolio
0.06%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$39.66 - $51.75 $2,260 - $2,949
57 Added 1.17%
4,911 $254,000
Q2 2024

Jul 31, 2024

SELL
$40.25 - $52.99 $21,936 - $28,879
-545 Reduced 10.09%
4,854 $201,000
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $2,590 - $2,937
54 Added 1.01%
5,399 $292,000
Q4 2023

Jan 29, 2024

BUY
$48.48 - $57.85 $2,375 - $2,834
49 Added 0.93%
5,345 $274,000
Q3 2023

Oct 27, 2023

BUY
$57.89 - $64.73 $2,373 - $2,653
41 Added 0.78%
5,296 $307,000
Q2 2023

Jul 28, 2023

BUY
$63.71 - $70.74 $2,293 - $2,546
36 Added 0.69%
5,255 $336,000
Q1 2023

Apr 28, 2023

BUY
$65.71 - $74.53 $2,168 - $2,459
33 Added 0.64%
5,219 $361,000
Q4 2022

Jan 20, 2023

BUY
$68.48 - $81.09 $2,054 - $2,432
30 Added 0.58%
5,186 $0
Q3 2022

Nov 21, 2022

BUY
$0.13 - $76.84 $3 - $2,305
30 Added 0.59%
5,156 $367,000
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $2,251 - $2,479
31 Added 0.61%
5,126 $395,000
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $19,981 - $23,959
-325 Reduced 6.0%
5,095 $372,000
Q4 2021

Jan 31, 2022

SELL
$53.63 - $62.52 $847,300 - $987,753
-15,799 Reduced 74.46%
5,420 $338,000
Q3 2021

Oct 28, 2021

SELL
$59.17 - $69.31 $81,536 - $95,509
-1,378 Reduced 6.1%
21,219 $1.26 Million
Q2 2021

Jul 28, 2021

SELL
$61.91 - $67.42 $46,370 - $50,497
-749 Reduced 3.21%
22,597 $1.51 Million
Q1 2021

May 03, 2021

BUY
$59.34 - $66.74 $1,839 - $2,068
31 Added 0.13%
23,346 $1.47 Million
Q4 2020

Jan 28, 2021

BUY
$57.74 - $65.43 $1,674 - $1,897
29 Added 0.12%
23,315 $1.45 Million
Q3 2020

Oct 30, 2020

BUY
$57.43 - $63.64 $11,198 - $12,409
195 Added 0.84%
23,286 $1.4 Million
Q2 2020

Jul 28, 2020

BUY
$54.82 - $64.09 $260,943 - $305,068
4,760 Added 25.97%
23,091 $1.36 Million
Q1 2020

May 01, 2020

BUY
$46.4 - $67.43 $81,060 - $117,800
1,747 Added 10.53%
18,331 $1.02 Million
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $94,089 - $122,731
1,912 Added 13.03%
16,584 $1.07 Million
Q3 2019

Oct 29, 2019

SELL
$42.77 - $50.71 $20,914 - $24,797
-489 Reduced 3.23%
14,672 $744,000
Q2 2019

Jul 29, 2019

BUY
$44.62 - $49.34 $181,603 - $200,813
4,070 Added 36.7%
15,161 $688,000
Q1 2019

Apr 30, 2019

BUY
$45.12 - $53.8 $1,037 - $1,237
23 Added 0.21%
11,091 $529,000
Q4 2018

Feb 15, 2019

BUY
$48.76 - $63.23 $56,464 - $73,220
1,158 Added 11.69%
11,068 $575,000
Q3 2018

Oct 31, 2018

BUY
$55.19 - $62.25 $1,103 - $1,245
20 Added 0.2%
9,910 $615,000
Q2 2018

Jul 31, 2018

BUY
$50.53 - $62.98 $1,162 - $1,448
23 Added 0.23%
9,890 $547,000
Q1 2018

May 04, 2018

BUY
$59.92 - $68.98 $76,757 - $88,363
1,281 Added 14.92%
9,867 $624,000
Q4 2017

Feb 02, 2018

BUY
$59.94 - $65.35 $92,187 - $100,508
1,538 Added 21.82%
8,586 $526,000
Q3 2017

Nov 01, 2017

BUY
$55.23 - $63.74 $389,261 - $449,239
7,048
7,048 $449,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bray Capital Advisors Portfolio

Follow Bray Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.